Bénard J |
[From metastatic osteolysis a painful message: beginning to understand with osteoprotegerin? |
2000 |
Bull Cancer |
pmid:11184451
|
Yamashita T et al. |
Retardation in bone resorption after bone marrow ablation in klotho mutant mice. |
2000 |
Endocrinology |
pmid:10614667
|
Hofbauer LC et al. |
The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. |
2000 |
J. Bone Miner. Res. |
pmid:10646108
|
Kanzawa M et al. |
Involvement of osteoprotegerin/osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by parathyroid hormone in mouse bone cells. |
2000 |
Eur. J. Endocrinol. |
pmid:10822231
|
Mukohyama H et al. |
The inhibitory effects of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on osteoclast formation are associated with upregulation of osteoprotegerin and downregulation of RANKL and RANK. |
2000 |
Biochem. Biophys. Res. Commun. |
pmid:10777696
|
Atkins GJ et al. |
Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. |
2000 |
J. Bone Miner. Res. |
pmid:10780856
|
Thompson SW and Tonge D |
Bone cancer gain without the pain. |
2000 |
Nat. Med. |
pmid:10802700
|
Honore P et al. |
Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. |
2000 |
Nat. Med. |
pmid:10802707
|
Onyia JE et al. |
In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. |
2000 |
J. Bone Miner. Res. |
pmid:10804015
|
Bateman TA et al. |
Osteoprotegerin mitigates tail suspension-induced osteopenia. |
2000 |
Bone |
pmid:10773583
|
Malyankar UM et al. |
Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. |
2000 |
J. Biol. Chem. |
pmid:10811631
|
Thirunavukkarasu K et al. |
The osteoblast-specific transcription factor Cbfa1 contributes to the expression of osteoprotegerin, a potent inhibitor of osteoclast differentiation and function. |
2000 |
J. Biol. Chem. |
pmid:10833509
|
Aubin JE and Bonnelye E |
Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption. |
2000 |
Medscape Womens Health |
pmid:10792853
|
Fata JE et al. |
The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. |
2000 |
Cell |
pmid:11051546
|
Miyamoto N et al. |
Spindle-shaped cells derived from giant-cell tumor of bone support differentiation of blood monocytes to osteoclast-like cells. |
2000 |
J. Orthop. Res. |
pmid:11052502
|
Kinpara K et al. |
Osteoclast differentiation factor in human osteosarcoma cell line. |
2000 |
J Immunoassay |
pmid:11071251
|
Kong YY et al. |
Osteoprotegerin ligand: a regulator of immune responses and bone physiology. |
2000 |
Immunol. Today |
pmid:11071528
|
Kobayashi Y et al. |
Force-induced osteoclast apoptosis in vivo is accompanied by elevation in transforming growth factor beta and osteoprotegerin expression. |
2000 |
J. Bone Miner. Res. |
pmid:11028444
|
Kaneda T et al. |
Endogenous production of TGF-beta is essential for osteoclastogenesis induced by a combination of receptor activator of NF-kappa B ligand and macrophage-colony-stimulating factor. |
2000 |
J. Immunol. |
pmid:11035059
|
Miyamoto T et al. |
An adherent condition is required for formation of multinuclear osteoclasts in the presence of macrophage colony-stimulating factor and receptor activator of nuclear factor kappa B ligand. |
2000 |
Blood |
pmid:11110710
|
|
Proposed standard nomenclature for new tumor necrosis factor members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President's Committee on Nomenclature. |
2000 |
Bone |
pmid:11113385
|
Takayanagi H et al. |
T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. |
2000 |
Nature |
pmid:11117749
|
Mancini L et al. |
Modulation of the effects of osteoprotegerin (OPG) ligand in a human leukemic cell line by OPG and calcitonin. |
2000 |
Biochem. Biophys. Res. Commun. |
pmid:11118297
|
Shalhoub V et al. |
Characterization of osteoclast precursors in human blood. |
2000 |
Br. J. Haematol. |
pmid:11122091
|
|
Proposed standard nomenclature for new tumor necrosis factor family members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President's Committee on Nomenclature. |
2000 |
J. Bone Miner. Res. |
pmid:11127193
|
Sakuma Y et al. |
Impaired bone resorption by lipopolysaccharide in vivo in mice deficient in the prostaglandin E receptor EP4 subtype. |
2000 |
Infect. Immun. |
pmid:11083800
|
Riggs BL |
The mechanisms of estrogen regulation of bone resorption. |
2000 |
J. Clin. Invest. |
pmid:11086020
|
Udagawa N et al. |
Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. |
2000 |
Endocrinology |
pmid:10965921
|
Yasuda H |
[A new paradigm of osteoclast biology: discovery of OCIF and ODF]. |
2000 |
Seikagaku |
pmid:10967683
|
Teitelbaum SL |
Bone resorption by osteoclasts. |
2000 |
Science |
pmid:10968780
|
Lacey DL et al. |
Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. |
2000 |
Am. J. Pathol. |
pmid:10934148
|
Quinn JM et al. |
Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation. |
2000 |
J. Bone Miner. Res. |
pmid:10934644
|
Min H et al. |
Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. |
2000 |
J. Exp. Med. |
pmid:10952716
|
Shiba H et al. |
Effects of ageing on proliferative ability, and the expressions of secreted protein, acidic and rich in cysteine (SPARC) and osteoprotegerin (osteoclastogenesis inhibitory factor) in cultures of human periodontal ligament cells. |
2000 |
Mech. Ageing Dev. |
pmid:10958924
|
López FJ |
New approaches to the treatment of osteoporosis. |
2000 |
Curr Opin Chem Biol |
pmid:10959765
|
Nakashima T et al. |
Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. |
2000 |
Biochem. Biophys. Res. Commun. |
pmid:10973797
|
Itoh K et al. |
Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors. |
2000 |
J. Bone Miner. Res. |
pmid:10976996
|
Schinke T and Karsenty G |
Vascular calcification--a passive process in need of inhibitors. |
2000 |
Nephrol. Dial. Transplant. |
pmid:10978374
|
Lorenzo J |
Interactions between immune and bone cells: new insights with many remaining questions. |
2000 |
J. Clin. Invest. |
pmid:10995785
|
Teng YT et al. |
Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. |
2000 |
J. Clin. Invest. |
pmid:10995794
|
Børset M et al. |
Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. |
2000 |
Blood |
pmid:11001907
|
Hofbauer LC and Heufelder AE |
Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. |
2000 |
J. Clin. Endocrinol. Metab. |
pmid:10902778
|
Rani CS and MacDougall M |
Dental cells express factors that regulate bone resorption. |
2000 |
Mol. Cell Biol. Res. Commun. |
pmid:10860862
|
Tsurukai T et al. |
Roles of macrophage-colony stimulating factor and osteoclast differentiation factor in osteoclastogenesis. |
2000 |
J. Bone Miner. Metab. |
pmid:10874596
|
Günther T and Schinke T |
Mouse genetics have uncovered new paradigms in bone biology. |
2000 |
Trends Endocrinol. Metab. |
pmid:10856921
|
Huang L et al. |
Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. |
2000 |
Am. J. Pathol. |
pmid:10702390
|
Capparelli C et al. |
Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. |
2000 |
Cancer Res. |
pmid:10706080
|
Makhluf HA et al. |
Age-related decline in osteoprotegerin expression by human bone marrow cells cultured in three-dimensional collagen sponges. |
2000 |
Biochem. Biophys. Res. Commun. |
pmid:10679262
|
Merewether LA et al. |
Development of disulfide peptide mapping and determination of disulfide structure of recombinant human osteoprotegerin chimera produced in Escherichia coli. |
2000 |
Arch. Biochem. Biophys. |
pmid:10683254
|
Ross FP |
RANKing the importance of measles virus in Paget's disease. |
2000 |
J. Clin. Invest. |
pmid:10712423
|
Tricot G |
New insights into role of microenvironment in multiple myeloma. |
2000 |
Lancet |
pmid:10675068
|
Chikatsu N et al. |
Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. |
2000 |
Biochem. Biophys. Res. Commun. |
pmid:10631114
|
Takami M et al. |
Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts. |
2000 |
Endocrinology |
pmid:11108286
|
Gori F et al. |
The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. |
2000 |
Endocrinology |
pmid:11108292
|
Clohisy DR et al. |
Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice. |
2000 |
J. Orthop. Res. |
pmid:11192258
|
Aubin JE and Bonnelye E |
Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. |
2000 |
Osteoporos Int |
pmid:11193242
|
Wise GE et al. |
Osteoprotegerin and osteoclast differentiation factor in tooth eruption. |
2000 |
J. Dent. Res. |
pmid:11201042
|
Kotake S et al. |
[Molecular mechanism of bone metabolism]. |
2000 |
Nippon Naika Gakkai Zasshi |
pmid:11215116
|
Kanematsu M et al. |
[Clinostat rotation culture modulates gene expression of osteoclastogenesis-regulating factors via a cyclic-AMP dependent mechanism]. |
2000 |
Biol. Sci. Space |
pmid:12561872
|
Saika M et al. |
17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. |
2001 |
Endocrinology |
pmid:11356664
|
Mackie PS et al. |
Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. |
2001 |
Br. J. Cancer |
pmid:11286476
|
Hofbauer LC et al. |
Osteoprotegerin, RANK, and RANK ligand: the good, the bad, and the ugly in rheumatoid arthritis. |
2001 |
J. Rheumatol. |
pmid:11327234
|
Hofbauer LC and Heufelder AE |
The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis. |
2001 |
Arthritis Rheum. |
pmid:11229454
|
Leach RJ et al. |
The genetics of Paget's disease of the bone. |
2001 |
J. Clin. Endocrinol. Metab. |
pmid:11231972
|
Luger NM et al. |
Osteoprotegerin diminishes advanced bone cancer pain. |
2001 |
Cancer Res. |
pmid:11358823
|
Zhang J et al. |
Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. |
2001 |
J. Clin. Invest. |
pmid:11375413
|
Kostenuik PJ and Shalhoub V |
Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. |
2001 |
Curr. Pharm. Des. |
pmid:11375772
|
Thirunavukkarasu K et al. |
Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. |
2001 |
J. Biol. Chem. |
pmid:11451955
|
Yun TJ et al. |
Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. |
2001 |
J. Immunol. |
pmid:11160187
|
Takemura M et al. |
Relationship between osteoprotegerin/osteoclastogenesis inhibitory factor concentration in synovial fluid and disease severity in individuals with osteoarthritis of the knee. |
2001 |
Metab. Clin. Exp. |
pmid:11172466
|
Gravallese EM et al. |
The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption. |
2001 |
Arthritis Res. |
pmid:11178122
|
Makiishi-Shimobayashi C et al. |
Interleukin-18 up-regulates osteoprotegerin expression in stromal/osteoblastic cells. |
2001 |
Biochem. Biophys. Res. Commun. |
pmid:11181055
|
Yano K et al. |
Immunological study on circulating murine osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF): possible role of OPG/OCIF in the prevention of osteoporosis in pregnancy. |
2001 |
Biochem. Biophys. Res. Commun. |
pmid:11594776
|
Brown JM et al. |
Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. |
2001 |
Clin. Cancer Res. |
pmid:11595685
|
Price PA et al. |
Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. |
2001 |
Arterioscler. Thromb. Vasc. Biol. |
pmid:11597934
|
Nemec K and Schubert-Zsilavecz M |
[Future therapies for metabolic bone diseases. New concepts and targets]. |
2001 |
Pharm Unserer Zeit |
pmid:11715689
|
Kuntz KA et al. |
An immunohistochemical study of osteoprotegerin in the human dental pulp. |
2001 |
J Endod |
pmid:11716077
|
Hofbauer LC and Schoppet M |
Serum measurement of osteoprotegerin--clinical relevance and potential applications. |
2001 |
Eur. J. Endocrinol. |
pmid:11720890
|
Ueland T et al. |
Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess--possible role in bone homeostasis. |
2001 |
Eur. J. Endocrinol. |
pmid:11720891
|
Chikazu D et al. |
Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors. |
2001 |
J. Bone Miner. Res. |
pmid:11697804
|
Khosla S |
Minireview: the OPG/RANKL/RANK system. |
2001 |
Endocrinology |
pmid:11713196
|
Seidel C et al. |
Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. |
2001 |
Blood |
pmid:11568016
|
Bateman TA et al. |
Osteoprotegerin ameliorates sciatic nerve crush induced bone loss. |
2001 |
J. Orthop. Res. |
pmid:11518255
|
Myoung H et al. |
Effects of a bisphosphonate on the expression of bone specific genes after autogenous free bone grafting in rats. |
2001 |
J. Periodont. Res. |
pmid:11519698
|
Haynes DR et al. |
The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. |
2001 |
J Bone Joint Surg Br |
pmid:11521937
|
Hofbauer LC and Schoppet M |
Osteoprotegerin: a link between osteoporosis and arterial calcification? |
2001 |
Lancet |
pmid:11498208
|
Sakai A et al. |
1alpha-Hydroxyvitamin D3 suppresses trabecular bone resorption by inhibiting osteoclastogenic potential in bone marrow cells after ovariectomy in mice. |
2001 |
J. Bone Miner. Metab. |
pmid:11498729
|
Ikeda T et al. |
Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones. |
2001 |
J. Bone Miner. Res. |
pmid:11499864
|
Thomas GP et al. |
Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. |
2001 |
J. Endocrinol. |
pmid:11479141
|
Allan GF et al. |
Induction of the progesterone receptor gene in estrogen target cells monitored by branched DNA signal amplification. |
2001 |
Steroids |
pmid:11546554
|
Feige U |
Osteoprotegerin. |
2001 |
Ann. Rheum. Dis. |
pmid:11890662
|
Lindberg MK et al. |
Estrogen receptor alpha, but not estrogen receptor beta, is involved in the regulation of the OPG/RANKL (osteoprotegerin/receptor activator of NF-kappa B ligand) ratio and serum interleukin-6 in male mice. |
2001 |
J. Endocrinol. |
pmid:11739008
|
Giuliani N et al. |
Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. |
2001 |
Blood |
pmid:11739153
|
Croucher PI et al. |
Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. |
2001 |
Blood |
pmid:11739154
|
Dhore CR et al. |
Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. |
2001 |
Arterioscler. Thromb. Vasc. Biol. |
pmid:11742876
|
Ramalho AC et al. |
Effect of oestradiol on cytokine production in immortalized human marrow stromal cell lines. |
2001 |
Cytokine |
pmid:11792122
|
Yano K et al. |
Synovial cells from a patient with rheumatoid arthritis produce osteoclastogenesis inhibitory factor/osteoprotegerin: reciprocal regulation of the production by inflammatory cytokines and basic fibroblast growth factor. |
2001 |
J. Bone Miner. Metab. |
pmid:11685652
|
Kawahara N et al. |
Two novel cucurbitacins, neocucurbitacins A and B, from the Brazilian folk medicine "Buchinha" (Luffa operculata) and their effect on PEBP2alphaA and OCIF gene expression in a human osteoblast-like Saos-2 cell line. |
2001 |
Chem. Pharm. Bull. |
pmid:11605678
|
Disthabanchong S and González EA |
Regulation of bone cell development and function: implication for renal osteodystrophy. |
2001 |
J. Investig. Med. |
pmid:11352181
|
Kotake S et al. |
Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. |
2001 |
Arthritis Rheum. |
pmid:11352231
|